CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction Positive recommendation for angiotensin receptor/neprilysin inhibitor: First medication approval for heart failure without "reduced ejection fraction" Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial Mechanical circulatory support devices in advanced heart failure: 2020 and beyond Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic Discovery SPECT and PET in ischemic heart failure Sex Differences in Cardiovascular Pathophysiology: Why Women Are Overrepresented in Heart Failure With Preserved Ejection Fraction Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus Myofibroblast Phenotype and Reversibility of Fibrosis in Patients With End-Stage Heart Failure Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction
|<<... 4 5 6 7 8 9 10 ...>>|

Clinical Trial2014 Sep 11;371(11):993-1004.

JOURNAL：N Engl J Med. Article Link

Angiotensin–neprilysin inhibition versus enalapril in heart failure

McMurray JJ, Packer M, PARADIGM-HF Investigators and Committees. Keywords: angiotensin receptor-neprilysin inhibitor LCZ696; enalapril; HFrEF; mortality; survival; hospitalization for heart failure

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top